Page 17 - Clinical Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kyoto University The Hidetoshi Sakurai laboratory reports two new markers that should advance iPS cell therapies for muscle degeneration. Muscular dystrophy describes a group of muscle degenerative congenital diseases. The severity and rates differ between disease and patient, but in all cases the degeneration progresses, sometimes leaving patients in wheelchairs and unable to breathe without artificial respiration. With no present cure, scientists are experimenting with the transplantation of muscle progenitor cells, but the amounts needed can only be made from stem cells such as i...

Kyoto University The Hotta lab shows that protection from cellular RNA enhances the genome editing of iPS cells. The ability for scientists to edit human genomic DNA has been around for decades. Such research has revealed how a single mutation in just one of the billions of base pairs in the human genome can cause destructive diseases. In the past decade, advances in CRISPR-Cas9 technology have taken DNA editing a major step farther and promise to revolutionize regenerative medicine. One of the biggest challenges for therapeutic application is the efficiency of precise genome editing. A new...

The global fluvoxamine market size was valued at USD 592 million in 2020 and projected to grow at a significant CAGR of 3% during the forecast period 2021 to 2027. The rising prevalence of anxiety and depression across the globe is a major factor to drive the market growth. Moreover, the increasing incidence of social anxiety disorder is expected to propel the market growth over the forecast period. The global fluvoxamine market is bifurcated into clinical application, distribution channel, and geography. On the basis of clinical application, the market is further segmented into obsessive-co...

The global hemodialysis blood tubing sets market size was valued at USD 1,733 million in 2020 and anticipated to register a significant CAGR of 5.2% during the forecast period 2021 to 2027 and expected to reach around USD 2.5 billion by 2027. The increasing prevalence of end-stage renal disease is a major factor to drive the market growth. Moreover, the increasing incidence of acid-base and electrolyte imbalance in patients suffering from chronic kidney disease is supporting the market growth. On the basis of clinical application, the market is further segmented into detoxification, mineral ...

Share this article Share this article ResearchAndMarkets.com's offering. This report provides a detailed analysis of Global Liquid Biopsy Industry. According to the research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026. A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer disease in the human body. Liquid biopsy assists medical practitioners as a source of genomic and proteomic knowledge in cancer patients by early detection of ci...